169545-27-1

Basic information

• Product Name: IRL-2500
• Synonyms: IRL-2500;N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN
• CAS NO: 169545-27-1
• Molecular Formula: C36H35N3O4
• Molecular Weight: 573.68
• Product Categories: Endothelin receptor
• Mol File: 169545-27-1.mol

Chemical Properties

• Boiling Point: 893.7 °C at 760 mmHg
• Flash Point: 494.3 °C
• Appearance: /
• Density: 1.246g/cm³
• Vapor Pressure: 2.56E-34mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: Desiccate at RT
• CAS DataBase Reference: IRL-2500(CAS DataBase Reference)
• NIST Chemistry Reference: IRL-2500(169545-27-1)
• EPA Substance Registry System: IRL-2500(169545-27-1)

Safety Data

• Hazardous Substances Data: 169545-27-1(Hazardous Substances Data)

Usage

Uses

IRL 2500 is a potent endothelin ETB selective antagonist.

Biological Activity

Potent endothelin receptor antagonist; shows some selectivity for ET B receptors (IC 50 values are 1.3 and 94 nM for ET B and ET A receptors respectively). Inhibits ET B receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo .

InChI:InChI=1/C36H35N3O4/c1-23-17-24(2)19-28(18-23)35(41)39(3)33(20-25-13-15-27(16-14-25)26-9-5-4-6-10-26)34(40)38-32(36(42)43)21-29-22-37-31-12-8-7-11-30(29)31/h4-19,22,32-33,37H,20-21H2,1-3H3,(H,38,40)(H,42,43)/t32-,33+/m0/s1

Upstream product

• 7524-52-9 (S)-tryptophan methyl ester hydrochloride 
• 169546-54-7 (R)-3-Biphenyl-4-yl-2-[(3,5-dimethyl-benzoyl)-methyl-amino]-propionic acid 
• 6613-44-1 3,5-dimethylbenzoyl chloride 
• 173189-77-0 N-methyl-(D)-(4-phenylphenyl)alanine methyl ester 
• 169546-53-6 (R)-3-Biphenyl-4-yl-2-[(3,5-dimethyl-benzoyl)-methyl-amino]-propionic acid methyl ester 
• 169885-19-2 (D)-3-(biphenyl-4-yl)-alanine methyl ester hydrochloride 
• 499-06-9 3,5-dimethylbenzoic acid 

Relevant articles and documents

BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN

This invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are allosteric effectors that reduce the oxygen-binding affinity of hemoglobin, which can enhance the efficacy of radiation therapy for cancer and which are useful for the treatment of ischemia and other conditions.

Antagonists of endothelin receptors

The present invention provides novel compounds having pharmacological properties represented by the general formula I STR1 processes for the manufacture, pharmaceutical compositions and the use of the compounds of formula I and salts thereof.

IRL 2500: A potent ET(B) selective endothelin antagonist

Combination of a glycine substitution scan on the C-terminal dodecapeptide analog of ET-1 and a substance P antagonist screen on the basis of a homology study of the rhodopsin superfamily of seven-transmembrane receptors yielded in the development of IRL 2500, a potent ET(B) selective endothelin antagonist.